Vistagen reports preliminary positive OLE data for fasedienol in SAD
Preliminary PALISADE-4 open-label extension data for fasedienol nasal spray suggest it was well-tolerated up to 12 months, with exploratory improvements on LSAS and SPIN over four months. Company plans to meet the FDA to consider a new registrational Phase 3.